Skin blood flow after transdermal S-nitrosothio-acetylglucose [3]

Lancet

Volumn 350, Issue 9075, 1997, Pages 410-411

  Khan, Faisel ^a   Greig, Iain R ^b   Newton, David J ^b   Butler, Anthony R ^b   Belch, Jill J F ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE DERIVATIVE; NITRIC OXIDE; S NITROSOTHIOACETYLGLUCOSE; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FINGER; FOREARM; HUMAN; HUMAN EXPERIMENT; LETTER; NORMAL HUMAN; PRIORITY JOURNAL; SKIN BLOOD FLOW; TISSUE OXYGENATION; TRANSDERMAL DRUG ADMINISTRATION; VASODILATATION;

EID: 0030798860     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)64133-5     Document Type: Article

References (5)

1. Coffman JD. Effects of endothelium-derived nitric oxide on skin and digital flow in humans. Am J Physiol 1994; 267: 2087-90.
2. Noon JP, Haynes WG, Webb DJ, Shore AC. Local inhibition of nitric oxide generation in man reduces blood flow in finger pulp but not in hand dorsum skin. J Physiol 1996; 490: 501-08.
3. Bauer JA, Fung HL. Differential hemodynamic effects and tolerance properties of nitroglycerine and S-nitrosothiol in experimental heart failure. J Pharmacol Exp Ther 1991; 256: 249-54.
4. Butler AR, Field RA, Greig IR, et al. An examination of some derivatives of S-nitroso-1-thiosugars as vasodilators. Nitric Oxide Biol Chem (in press).
5. Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJF. Oral 1-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon. Arthrit Rheum 1997; 40: 352-57.